drugset / Trial / NCT05008445
Study of LM-102 in Patients With Advance Solid Tumors
Phase 1/2
Terminated
11 enrolled
LaNova Medicines Development Co., Ltd.
First Affiliated Hospital of Harbin Medical University · collabFirst Affiliated Hospital of Zhejiang University · collabShanghai Zhongshan Hospital · collabSir Run Run Shaw Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open label Phase I/II trial of LM-102 injection, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2). It is being tested in advanced solid tumors including gastric cancer/gastroesophageal junction adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, esophageal adenocarcinoma and ovarian mucous carcinoma.
Timeline
- Start
- 2021-10-06
- Primary completion
- 2023-02-08
- Completion
- 2023-02-28
Outcome
Outcome not reported
Stopped (Business): “company adjusted strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TECOTABART | Monoclonal antibody | 3 mg/kg | — |
| Subject | TECOTABART | Monoclonal antibody | 10 mg/kg | — |
| Subject | TECOTABART | Monoclonal antibody | 20 mg/kg | — |
| Subject | TECOTABART | Monoclonal antibody | 30 mg/kg | — |
| Subject | TECOTABART | Monoclonal antibody | 40 mg/kg | — |